OncoSec Medical Inc (ONCSQ)

[chickpea598]

Merck presented data today with positive results for Keytruda besting Bristol Myers in Lung Cancer as first line therapy. Now how are they going to take their best-in-class Keytruda for lung cancer and treat the 70% of the population who are non-responsive to pd-1 therapy?......ONCOSEC combo therapy with Keytruda!


The Keytruda study results "may establish a new standard of care" for first-line treatment of lung cancer patients whose tumors have high levels of PD-L1, Bruce E. Johnson, a lung-cancer specialist at Dana-Farber Cancer Institute in Boston, wrote in a NEJM editorial accompanying the Keytruda results.


Maybe a combo of Keytruda and Immunopulse IL-12 would earn a first-line therapy indication for the 70% of the population who do not respond to pd-1 therapy alone and who would rather not be poisoned with chemo and radiation.